Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;14(2):73-87.
doi: 10.1080/17469899.2019.1596026. Epub 2019 Mar 29.

A review of treatment for retinopathy of prematurity

Eric D Hansen  1 , M Elizabeth Hartnett  1
Affiliations

A review of treatment for retinopathy of prematurity

Eric D Hansen et al. Expert Rev Ophthalmol. 2019.

Abstract

Introduction: Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide.

Areas covered: Recent methods to identify and manage treatment-warranted vascularly active ROP are recognized and being compared to standard care by laser treatment in prospective large-scale clinical studies. Pharmacologic anti-angiogenic (anti-VEGF) treatment has changed the natural history of vascularly active ROP by reducing stage 3 intravitreal neovascularization and extending physiologic retinal vascularization in many infants. Tractional retinal detachments in stage 4 ROP after treatment with anti-VEGF agents show additional fibrovascular complexity compared to eyes treated with laser only. We review current management and outcomes for vascularly active and fibrovascular retinal detachment in ROP (stages 3, 4, 5 ROP), highlighting the evidence from recent clinical studies. Included are technical details important in surgery for retinal detachment in ROP. Literature searches were employed through PubMed.

Expert opinion: Methods in pediatric imaging, safer pharmacologic treatments, and surgical techniques continue to advance to improve future ROP outcomes.

Keywords: angiogenesis; laser; lens-sparing; retinal detachment; retinopathy of prematurity (ROP); scleral buckle; stage 4 or 5 ROP; surgical outcomes; vascular endothelial growth factor inhibitors (anti-VEGF); vitrectomy.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.
Treatment-Warranted and Retinal Detachment in ROP Retcam images of A. Type 1 ROP in zone II, stage 3+. B. Type 1 ROP in zone I- posterior zone II, stage 3+. C. Stage 4 ROP with a combination of exudative and tractional elements. Images by Melissa Chandler, CRA, OCT-C
Figure 2.
Figure 2.
Infant and Adult Eye Artist drawing depicting estimated differences in A. Infant eye – Safe entry into the vitreous is through pars plicata, which is less than 1 mm wide; lens is more spherical; vitreous is about 1 mL, and B. Adult eye – Safe entry into vitreous is through pars plana – 3.5–4.0 mm posterior to the limbus; vitreous is ~4 mL. Drawn by James Gilman, CRA, FOPS
Figure 3.
Figure 3.
Tractional Forces in Stage 4 ROP Addressed in Lens-sparing Vitrectomy A. Artist drawing of lens-sparing vitrectomy demonstrating vitreoretinal contractile forces from (1) ridge to ora serrata and anterior retina, (2) ridge and lens, (3) circumferentially from ridge to ridge, (4) ridge to the optic nerve, and (5) over the optic nerve. After anti-VEGF treatment, additional tractional components occur over the optic nerve and in the mid peripheral retina where previous ridge occurred. Drawn by James Gilman, CRA, FOPS B. Optical coherence tomogram (OCT) through ridge of stage 4 ROP showing retinal detachment and vitreoretinal tractional components. Image obtained by Glen Jenkins, CRA, OCT-C
Figure 4.
Figure 4.
Fibrovascular Contraction after Anti-VEGF in Former APROP A. Montage of mid-peripheral vitreoretinal traction in region of previous stage 3 ROP at posterior vascular/avascular junction prior to extension of physiologic vascularization after anti-VEGF treatment. Laser marks noted in periphery. B. OCT through superotemporal ridge shows evidence of tractional retinal detachment and retinoschisis. Images by Glen Jenkins, CRA, OCT-C.
Figure 4.
Figure 4.
Meridional External Element Artist drawing of an external element to support peripheral traction causing a localized retinal fold and reduce further macula dragging. Drawn by James Gilman, CRA, FOPS
See this image and copyright information in PMC

References

    1. Gilbert C Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control. Early Human Development. 2008. 2/2008;84(2):77–82. - PubMed
    1. Painter SL, Wilkinson AR, Desai P, et al. Incidence and treatment of retinopathy of prematurity in England between 1990 and 2011: database study. The British journal of ophthalmology. 2015. June;99(6):807–11. doi: 10.1136/bjophthalmol-2014-305561. PubMed PMID: 25427778; eng. - DOI - PubMed
    1. Kim SJ, Port AD, Swan R, et al. Retinopathy of prematurity: a review of risk factors and their clinical significance. Survey of ophthalmology. 2018. Sep-Oct;63(5):618–637. doi: 10.1016/j.survophthal.2018.04.002. PubMed PMID: 29679617; PubMed Central PMCID: PMCPMC6089661. eng. - DOI - PMC - PubMed
    1. Blencowe H, Moxon S, Gilbert C. Update on Blindness Due to Retinopathy of Prematurity Globally and in India. Indian pediatrics. 2016. November 7;53 Suppl 2:S89–s92. PubMed PMID: 27915313; eng. - PubMed
    1. Ludwig CA, Chen TA, Hernandez-Boussard T, et al. The Epidemiology of Retinopathy of Prematurity in the United States. Ophthalmic surgery, lasers & imaging retina. 2017. July 1;48(7):553–562. doi: 10.3928/23258160-20170630-06. PubMed PMID: 28728176; eng. - DOI - PubMed

LinkOut - more resources